olanzapine

P2, N=233, Completed, Astellas Pharma Global Development, Inc. | Phase classification: P2a --> P2

P=N/A, N=200, Recruiting, Centre Hospitalier St Anne | Not yet recruiting --> Recruiting

P1, N=95, Active, not recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting --> Active, not recruiting

ARI de-sensitizes Fao cells to stress signaling, while OLA has the opposite effect. These findings contribute to our understanding of the metabolic risks associated with prolonged AAP use and may inform future therapeutic strategies.

Our results indicate that serum IL-2, IL-8, IL-10, and TNF-α levels may be involved in the pathophysiological mechanisms of schizophrenia and correlate with the effects of olanzapine.

P3, N=164, Completed, Cairo University | Recruiting --> Completed

P=N/A, N=200, Not yet recruiting, Centre Hospitalier St Anne

The effect of antiemetics (dexamethasone, ondansetron, fosaprepitant, and olanzapine) on emesis induced by zolbetuximab was investigated. Fosaprepitant showed suppressive effects on emesis, and use of dexamethasone or concomitant use of fosaprepitant with other antiemetics tended to alleviate gastric tissue damage. The onset of emesis in humans receiving zolbetuximab may be associated with damage in the gastric mucosa, and antiemetics may mitigate gastrointestinal adverse events.

P=N/A, N=1000, Not yet recruiting, Peking University Sixth Hospital; Peking University Sixth Hospital

Olanzapine 5mg for 6 days with 5-HT3RA and dexamethasone appears effective for T-DXd-treated patients to prevent delayed and persistent nausea and vomiting.

P3, N=172, Not yet recruiting, Augusta University

P2, N=170, Enrolling by invitation, Englewood Hospital and Medical Center | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Dec 2026

P=N/A, N=200, Completed, Central South University | Recruiting --> Completed

P2, N=156, Not yet recruiting, Second Affiliated Hospital of Nanchang University

P=N/A, N=200, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Aug 2027 --> Dec 2027

P=N/A, N=48, Recruiting, Rajavithi Hospital | Not yet recruiting --> Recruiting

However, cotreatment with Cevimeline significantly reversed the lipid metabolic disturbance and adipose tissue accumulation, as well as the upregulation of the hepatic Alk signaling caused by Olanzapine. This study demonstrates evidence that Olanzapine may cause metabolic disturbance by modulating hepatic Alk signaling via M3R, which provides novel insight for modulating the hepatic Alk signaling and potential interventions for targeting metabolic disorders.

We identify a new mechanism by which OLZ ameliorates chronic stress-enhanced tumorigenesis and chemoresistance. OLZ suppresses mPFC-NE-CLOCK axis to reverse chronic stress-induced anxiety-like behaviors and lung cancer stemness. Decreased NE-releasing prevents activation of ADRB2-cAMP-PKA-CREB pathway to inhibit CLOCK transcription, thus reversing lung cancer stem-like traits and chemoresistance under chronic stress.

P3, N=138, Recruiting, Mahidol University

P3, N=300, Recruiting, Qingdao Central Hospital

P3, N=80, Recruiting, Louisiana State University Health Sciences Center Shreveport

After that, Olaparib → Bmab + PTX therapy was performed, but in August of X+2, the patient presented with headache and vomiting and visited the emergency department again, where he was diagnosed with re-exacerbation of carcinomatous meningitis and was admitted urgently...The administration time of BET and GLY was changed to continuous administration, and acetazolamide was added, which extended the time for symptom relief. Furthermore, headache was alleviated with morphine, and nausea was alleviated with olanzapine, and symptom relief was achieved without sedation until the end. [Discussion] There are only a limited number of drugs that can alleviate the symptoms of headache and nausea caused by cancer meningitis. In addition to BET and GLY, the combined use of diuretics, opioids, and antiemetics was considered to be one method of alleviating symptoms

P3, N=62, Terminated, University of Michigan Rogel Cancer Center | Active, not recruiting --> Terminated; Lack of Patient Population

P3, N=360, Recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Apr 2024 --> May 2026

Currently, addressing contributing conditions (hypothyroidism, hypogonadism, and adrenal insufficiency), managing nutrition impact symptoms leading to decreased oral intake (nausea, constipation, dysgeusia, stomatitis, mucositis, pain, fatigue, depressed mood, or anxiety), and the addition of pharmacologic agents when appropriate (progesterone analog, corticosteroids, and olanzapine) is recommended. In Japan, the clinical practice has changed based on the availability of Anamorelin, a ghrelin receptor agonist that improved lean body mass, weight, and appetite-related quality of life (QoL) compared to a placebo, in phase III trials...In the future, a single therapeutic agent or perhaps multiple medications targeting the various mechanisms of CC may prove to be an effective strategy. Ideally, these medications should be incorporated into a multimodal interdisciplinary approach that includes exercise and nutrition.

P3, N=0, Withdrawn, Mayo Clinic | Trial completion date: Jun 2024 --> Dec 2024

Dexmedetomidine is effective in reducing early POD in elderly patients post-thoracolumbar compression fracture surgery. It also decreases IL-6 and TNF-α levels, indicating its potential in managing postoperative inflammatory responses. Treatment with 0.5 mM DEX significantly modulated Phospho-ERK1/2 and Phospho-JNK expressions in postoperative CSF samples, indicating a dose-dependent effect on reducing inflammation. This study contributes to understanding DEX's role in improving postoperative outcomes in elderly patients.

P2, N=66, Recruiting, OHSU Knight Cancer Institute | Suspended --> Recruiting | N=44 --> 66 | Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Jun 2025

P3, N=1351, Completed, University of Rochester NCORP Research Base | Recruiting --> Completed | Trial completion date: Jun 2024 --> Feb 2024

P3, N=675, Active, not recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Trial completion date: Oct 2025 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Mar 2024

P4, N=13, Terminated, Sumitomo Pharma (Suzhou) Co., Ltd. | N=162 --> 13 | Active, not recruiting --> Terminated; Company's business decision

P3, N=72, Recruiting, Tan Tock Seng Hospital | Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024

P4, N=1, Completed, Pachankis, Yang I., M.D.

P1, N=95, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting --> Recruiting

P3, N=87, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

P1, N=116, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting --> Recruiting

P1, N=19, Completed, Sumitomo Pharma America, Inc. | Recruiting --> Completed | N=60 --> 19

P3, N=627, Not yet recruiting, Fudan University

P1, N=36, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting --> Recruiting

P1, N=95, Not yet recruiting, Teva Branded Pharmaceutical Products R&D, Inc.

P1, N=116, Not yet recruiting, Teva Branded Pharmaceutical Products R&D, Inc.

P4, N=80, Recruiting, Icahn School of Medicine at Mount Sinai | Initiation date: Feb 2024 --> May 2024